Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 3/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 11/20 | 0.45 |
| ▸ | IL1B | P01584 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2033985 | 0.86 | CNR2 (0.47) | CNR2CNR1P2RX7IL1B | |
| SCHEMBL2036321 | 0.81 | ALDH1A1 (0.54) | CNR2CNR1P2RX7IL1BALDH1A1 | |
| SCHEMBL2037089 | 0.80 | P2RX7 (0.65) | P2RX7IL1B | |
| SCHEMBL2035593 | 0.80 | P2RX7 (0.57) | CNR2CNR1P2RX7IL1BMAPT | |
| SCHEMBL2035744 | 0.80 | CNR1 (0.49) | CNR2CNR1P2RX7IL1BALDH1A1 | |
| SCHEMBL2033486 | 0.80 | MCL1 (0.52) | CNR2CNR1P2RX7IL1BALDH1A1 | |
| SCHEMBL2034386 | 0.78 | CNR1 (0.47) | CNR2CNR1P2RX7IL1BALDH1A1 | |
| SCHEMBL2037949 | 0.77 | P2RX7 (0.62) | CNR2CNR1P2RX7IL1B | |
| SCHEMBL2040010 | 0.77 | CNR2 (0.48) | CNR2CNR1P2RX7IL1BALDH1A1 | |
| SCHEMBL2034373 | 0.77 | ALDH1A1 (0.50) | CNR2CNR1P2RX7IL1BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516419-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-10-31 | — | — | EP | disclosed |
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| WO-2011079102-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | SANOFI (FR) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245161-A1 | INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS | TPSAB1, TPSB2, TPSD1 | CNR2 113/4885TSHR 1421/4885CNR1 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.